The Sculptique Aesthetics
Muscle Loss on Ozempic and Mounjaro: What the Scale Is Actually Losing
Semaglutide and tirzepatide remove fat, and some lean tissue goes with it. Protein and strength work are the evidence-based response. A research peptide is not a muscle shield.

The number on the scale is a mix of fat, water and lean tissue. When it falls quickly I ask what you are eating and whether you are lifting, long before I talk about skin or surgery.
— Dr. Aamod Rao
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) can take weight off faster than most diets people have managed alone. Fat is the point of that treatment. Lean tissue falls as well. Lean tissue is muscle, and also organ protein and water bound up with glycogen. Calling all of it "muscle" is a little loose. Ignoring it, because the jeans fit, is how people arrive looking lighter and also less strong, with a face that has emptied in places they did not expect.
This is the piece patients ask about while the prescription is still working. What to do when the skin has already failed to shrink is a different article: loose skin after Ozempic or Mounjaro. The facial version is volume loss in the face. Read those for surgery and filler. Read this for the months when the scale is still moving.
What the trials imply, without a fake percentage
In the large semaglutide and tirzepatide programmes, people lost substantial weight, and body-composition work shows fat as the larger share of that loss. Lean mass falls too. You will see a tidy percentage recycled on social media, often "about 40 percent of the weight was muscle." Treat recycled percentages with suspicion. Substudies differ in who was scanned, how lean mass was defined, and whether the share of lean mass in the body actually rose even as the kilograms of lean mass fell. Both of these can be true: you lost lean kilograms, and a greater fraction of what remained was lean, because fat fell faster.
The practical reading does not need the argument about the exact fraction. If you lose weight quickly and you do not lift, and your protein intake falls because your appetite fell, you will give up more strength than you had to.
Newer injections such as retatrutide, still investigational, will face the same body-composition question if they produce large losses. A new mechanism is not a free pass around muscle. Our retatrutide explainer is about the drug, not a promise that the scale will be pure fat.
What actually changes the odds
Three things have a basis. A research peptide does not.
Keep eating enough protein. Appetite suppression is the drug working, and it is also how protein intake quietly collapses. The prescribing doctor or a dietitian should set a target for you. A blog should not invent your gram-per-kilo figure. Do not "eat as little as possible" because the injection made that easy.
Train the muscle you want to keep. Two or three sessions a week of proper resistance work, not only walking, is the signal muscle understands during a calorie deficit. Walking is good for the rest of the plan. It is a weak signal for keeping thigh and shoulder muscle.
Do not chase the loss with a second unproven drug. MOTS-c, growth-hormone peptides and repair blends are being sold as muscle protection for people on GLP-1 drugs. That stack is a theory from other corners of the internet. It is not a result from the semaglutide or tirzepatide trials. MOTS-c has mouse data and blood-level studies, not a role as a companion to Mounjaro. Adding it is not a conservative step. It is a second experiment.
Tell the doctor who prescribed the injection about your training, your protein, and any dizziness, hair shedding or marked weakness. Dose adjustments belong to that prescriber. We do not take over a metabolic prescription from a plastic-surgery consultation, and we do not tell you to stop a medicine that another doctor is monitoring.
What this clinic looks at afterwards
While the weight is still dropping, surgery is early. Skin and muscle both need a stable weight before an operation is planned. That judgement is laid out in the loose-skin article, including abdomen, arms, breasts and thighs.
The face can change earlier than the abdomen, because facial fat is a small pad and cameras are cruel. Filler or fat transfer is a discussion once the loss has slowed enough that we are not filling a moving target. Details are in the facial-volume article. A skin-quality treatment will not put a cheek back.
December weddings make this urgent for a lot of Mumbai patients in November. Urgency is a reason to be conservative. It is a poor reason to stack a new injectable, a new peptide and a lower calorie target into the same fortnight.
Frequently asked questions
They produce weight loss that includes a loss of lean mass, of which muscle is a part. Fat is still the larger share in the body-composition studies. How much strength you keep depends heavily on protein and resistance training while the appetite is suppressed.
No. Scans of lean mass include water and organ protein as well as skeletal muscle. Strength in the gym is the measure you can feel. The scan is the measure a paper reports. They are related and they are not identical.
The one your prescribing doctor or dietitian sets for your weight, your kidney function and your intake now. Copying a gram-per-kilo figure from a reel skips the part where someone checks that it fits you.
Not on any evidence we can use. Do not add MOTS-c, a GLOW vial or a growth-hormone blend as a shield. Train, eat protein, and stay under the doctor who prescribed the injection.
When the weight has been stable and the change you dislike is skin or volume, not a scale that is still falling. Bring both the face and the body questions to one consultation if you need to. We would rather stage them than operate in the middle of the loss.
Stability first
If you are on a weight-loss injection and you want a plan for strength now, or a realistic date for skin or facial work later, book a consultation and bring the name of the medicine and how long you have been on it.
Book a consultation · Loose skin after weight-loss drugs · Facial volume after weight loss
Sources
Checked 18 November 2026:
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Body-composition substudies of the semaglutide and tirzepatide programmes report loss of fat mass as the larger component, with lean mass reduced as well. Exact percentages vary by substudy and should not be copied from social media as a personal prediction.
- Clinic timing: contouring surgery and facial filling are discussed after the weight is stable. See the linked articles.
This article is for educational purposes only. It is not medical advice and does not replace a consultation with a qualified clinician.








